134 related articles for article (PubMed ID: 34044119)
1. Synthesis of propargylamine mycophenolate analogues and their selective cytotoxic activity towards neuroblastoma SH-SY5Y cell line.
Silalai P; Pruksakorn D; Chairoungdua A; Suksen K; Saeeng R
Bioorg Med Chem Lett; 2021 Aug; 45():128135. PubMed ID: 34044119
[TBL] [Abstract][Full Text] [Related]
2. Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors.
Wünsch M; Senger J; Schultheisz P; Schwarzbich S; Schmidtkunz K; Michalek C; Klaß M; Goskowitz S; Borchert P; Praetorius L; Sippl W; Jung M; Sewald N
ChemMedChem; 2017 Dec; 12(24):2044-2053. PubMed ID: 29120081
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of pentacycloundecane and hexacycloundecane propargylamine derivatives as multifunctional neuroprotective agents.
Zindo FT; Malan SF; Omoruyi SI; Enogieru AB; Ekpo OE; Joubert J
Eur J Med Chem; 2019 Feb; 163():83-94. PubMed ID: 30503945
[TBL] [Abstract][Full Text] [Related]
4. Novel propargylamine-based inhibitors of cholinesterases and monoamine oxidases: Synthesis, biological evaluation and docking study.
Krátký M; Vu QA; Štěpánková Š; Maruca A; Silva TB; Ambrož M; Pflégr V; Rocca R; Svrčková K; Alcaro S; Borges F; Vinšová J
Bioorg Chem; 2021 Nov; 116():105301. PubMed ID: 34492558
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of antitumor-active betulinic acid-derived hydroxypropargylamines by copper-catalyzend mannich reactions.
Csuk R; Nitsche C; Sczepek R; Schwarz S; Siewert B
Arch Pharm (Weinheim); 2013 Mar; 346(3):232-46. PubMed ID: 23404652
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid.
Siebert A; Deptuła M; Cichorek M; Ronowska A; Cholewiński G; Rachon J
Anticancer Agents Med Chem; 2021; 21(4):462-467. PubMed ID: 32416705
[TBL] [Abstract][Full Text] [Related]
7. Newer human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents.
Shah CP; Kharkar PS
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):972-977. PubMed ID: 29792360
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine.
Bar-Am O; Weinreb O; Amit T; Youdim MB
FASEB J; 2005 Nov; 19(13):1899-901. PubMed ID: 16148027
[TBL] [Abstract][Full Text] [Related]
9. Gold(III) Salen complex-catalyzed synthesis of propargylamines via a three-component coupling reaction.
Lo VK; Liu Y; Wong MK; Che CM
Org Lett; 2006 Apr; 8(8):1529-32. PubMed ID: 16597102
[TBL] [Abstract][Full Text] [Related]
10. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2.
Yi H; Maruyama W; Akao Y; Takahashi T; Iwasa K; Youdim MB; Naoi M
J Neural Transm (Vienna); 2006 Jan; 113(1):21-32. PubMed ID: 15843867
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
12. New conjugates of mycophenolic acid and their antiproliferative activity.
Prejs M; Cholewinski G; Siebert A; Trzonkowski P; Dzierzbicka K
J Asian Nat Prod Res; 2016 Nov; 18(11):1057-62. PubMed ID: 27229268
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Xu YX; Wang H; Li XK; Dong SN; Liu WW; Gong Q; Wang TD; Tang Y; Zhu J; Li J; Zhang HY; Mao F
Eur J Med Chem; 2018 Jan; 143():33-47. PubMed ID: 29172081
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Biological Evaluation of Acridine/Acridone Analogs as Potential Anticancer Agents.
Gensicka-Kowalewska M; Cichorek M; Ronowska A; Deptuła M; Klejbor I; Dzierzbicka K
Med Chem; 2019; 15(7):729-737. PubMed ID: 30324889
[TBL] [Abstract][Full Text] [Related]
15. Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.
Zindo FT; Joubert J; Malan SF
Future Med Chem; 2015; 7(5):609-29. PubMed ID: 25921401
[TBL] [Abstract][Full Text] [Related]
16. Antioxidant properties of newly synthesized N-propargylamine derivatives of nitroxyl: a comparison with deprenyl.
Kochman A; Skolimowski J; Gebicka L; Metodiewa D
Pol J Pharmacol; 2003; 55(3):389-400. PubMed ID: 14506318
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Tröger's base analogues as selective inhibitors against human breast cancer cell line: design, synthesis and cytotoxic evaluation.
Manda BR; Alla M; Ganji RJ; Addlagatta A
Eur J Med Chem; 2014 Oct; 86():39-47. PubMed ID: 25140752
[TBL] [Abstract][Full Text] [Related]
18. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
19. R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells.
Lai CT; Yu PH
Toxicol Appl Pharmacol; 1997 Jan; 142(1):186-91. PubMed ID: 9007048
[TBL] [Abstract][Full Text] [Related]
20. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing.
Yogev-Falach M; Amit T; Bar-Am O; Youdim MB
FASEB J; 2003 Dec; 17(15):2325-7. PubMed ID: 14525944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
